Table of Contents
I. Addressing Health Disparities With Neuroscience Webinar:
II. RFA-DA-22-011 Large Scale Mapping and/or Molecular Profiling of Ensembles and/or Cell-Types Mediating Opioid Action in the Rodent Brain (R01 - Clinical Trial Not Allowed)
III. PAR-20-225 Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)
IV. NOT-DA-20-030 Notice of Special Interest (NOSI): Human Molecular Genetics of Substance Use Disorders
I. Addressing Health Disparities With Neuroscience Webinar:
“July 23rd, 2021 from 11:30am-1:00pm EDT: The NIDA Division of Neuroscience and Behavior’s Diversity and Inclusion Group invites you to the virtual seminar Addressing Health Disparities With Neuroscience: “Social Environment and the Developing Brain”. This new virtual seminar series brings together two scientists from disparate fields to discuss how basic, translational and clinical neuroscience research can inform, and be informed by, research on health disparities and health inequities. The July 2021 seminar, Social Environment and the Developing Brain, will explore how social and environmental factors can act as important predictors of neurocognitive development, and will feature Dr. Kimberly Noble, M.D., Ph.D. (Teacher’s College, Columbia University) and Dr. Daniel Hackman, Ph.D. (USC Suzanne Dworak-Peck School of Social Work, University of Southern California). Zoom registration link is available here.”
II. RFA-DA-22-011 Large Scale Mapping and/or Molecular Profiling of Ensembles and/or Cell-Types Mediating Opioid Action in the Rodent Brain (R01 - Clinical Trial Not Allowed) https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-011.html Application due date: October 15, 2021 due by 5:00 PM local time of applicant organization.
This funding opportunity announcement aims to support research that employs innovative scalable technologies to identify, map, and profile cellular ensembles and/or cell-types that produce and/or respond to opioids or that are engaged during different stages of opioid use (acute, chronic, withdrawal, abstinence, relapse). Emphasis is on single-cell resolution approaches that enable multimodal high-throughput functional mapping, anatomical characterization and molecular profiling of cell assemblies identified as targets of, or as primary sources of opioids in the brain.
This award uses a R01 mechanism with a budget cap of $700K direct cost per year. Multidisciplinary collaborative approaches are encouraged. This is a reissue of PAR-20-241 but new applications only are accepted.
Address inquiries to
satterleej@nida.nih.go
olivier.berton@nih.gov
III. PAR-20-225 Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional) https://grants.nih.gov/grants/guide/pa-files/PAR-20-225.htmlApplication Due Dates: October 19, 2021, October 19, 2022 by 5:00 PM local time of applicant organization. All applications are due by 5:00 PM local time of applicant organization.
Avenir means future in French, and this award looks toward the future by supporting early stage investigators proposing highly innovative studies. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field. NIDA has developed two Avenir Award Programs, one for HIV/AIDS research and the other for genetics or epigenetics studies.
The Genetics or Epigenetics of Substance Use Disorders Avenir Award program supports early stage investigators proposing highly innovative studies that open new areas of research for the genetics or epigenetics of addiction. These may be novel methods or approaches that can potentially be applied to the analysis of the genetics or epigenetics of addiction. Investigators outside the field of addiction interested in applying their novel approaches to the genetics or epigenetics of addiction are encouraged to apply. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field of genetics or epigenetics of substance use disorders.
NOT-DA-20-030 Notice of Special Interest (NOSI): Human Molecular Genetics of Substance Use Disorders https://grants.nih.gov/grants/guide/notice-files/NOT-DA-20-030.html
Application Due Dates: Standard Due Dates Apply.
This Notice encourages applications for research projects that identify, validate and/or functionally characterize loci, genetic variations and haplotypes that are associated with vulnerability to addiction and that potentially inform the likelihood of responsiveness to treatment. Data may be collected from the general population, special populations, recent admixed populations, and/or electronic medical records (EMR). Secondary data analysis of data collected from the general population, special populations, recent admixed populations, and/or animal models is also appropriate for this notice. Investigators are encouraged to include functional characterization, gene x gene interactions, gene x environment interactions, and gene x environment x development interactions.
The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-
